⌘K
t
On 26 October 2021, Mr Ali Mortazavi, Chief Executive Officer of e-therapeutics plc, purchased 275,000 Ordinary Shares at 36.5 pence each, totalling an aggregated value of £100,375. Following this transaction, Mr Mortazavi's beneficial interest is 50,941,666 Ordinary Shares, which represents 9.9% of the Company's total issued share capital.
| Date | 26 Oct 2021 |
| Time | 13:55:26 |
| Category | Director/PDMR dealings |
| ID | 3181Q |
e-therapeutics plc
("e-therapeutics" or the "Company")
Director Dealing
Oxford, UK, 26 October 2021 - e-therapeutics plc (AIM: ETX; OTCQX: ETXPF), a specialist in computational drug discovery with a focus on developing RNA interference ("RNAi") therapeutics, announces the following dealing in the Company's ordinary shares of 0.1 pence each ("Ordinary Shares").
Earlier today, Mr Ali Mortazavi, the Company's Chief Executive Officer, purchased 275,000 Ordinary Shares at a price of 36.5 pence each.
Following the transaction, Mr Mortazavi is benefically interested in 50,941,666 Ordinary Shares, representing 9.9% of the Company's total issued share capital.
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further details:
|
1 |
Details of the person discharging managerial responsibilities/person closely associated |
|
|
a) |
Name |
Ali Mortazavi |
|
2 |
Reason for the notification |
|
|
a) |
Position/status |
Chief Executive Officer |
|
b) |
Initial notification/ Amendment |
Initial notification |
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|
|
a) |
Name |
e-therapeutics plc |
|
b) |
LEI |
21380049RHSSJXWKYT18 |
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|
|
a) |
Description of the financial instrument, type of instrument Identification code |
Ordinary Shares of 0.1 pence
ISIN: GB00B2823H99 |
|
b) |
Nature of the transaction |
Purchase of shares |
|
c) |
Price(s) and volume(s) |
275,000 ordinary shares at a price of 36.5 pence per share |
|
d) |
Aggregated information - Aggregated volume - Price
|
275,000 ordinary shares 36.5 pence per share Aggregated value: £100,375 |
|
e) |
Date of the transaction |
26 October 2021
|
|
f) |
Place of the transaction |
AIM |
Enquiries:
|
e-therapeutics plc |
Tel: +44 (0)1993 883 125 |
|
Ali Mortazavi, CEO |
www.etherapeutics.co.uk |
|
Karl Keegan, CFO |
|
|
|
|
|
SP Angel Corporate Finance LLP |
Tel: +44(0)20 3470 0470 |
|
Nominated Adviser and Broker |
|
|
Matthew Johnson/Caroline Rowe (Corporate Finance) |
|
|
Vadim Alexandre/Rob Rees (Corporate Broking) |
|
About e-therapeutics plc
e-therapeutics plc is an Oxford, UK-based company integrating computational power and biology to accelerate the discovery of life-transforming medicines. The Company has developed and validated a powerful, disease and modality agnostic computational approach to drug discovery, leveraging its industry-leading expertise in network biology to fully capture and interrogate human disease complexity.
The Company's multi-disciplinary team builds computational models of biological functions to transform the search for new medicines, interventions, mechanisms and genetic support. Its biology-led in silico laboratory enables rapid hypothesis generation and phenotypic screening of millions of compounds leading to 100-1000x higher hit rates in the wet lab and successful mode of action elucidation. Novel targets can also be identified, prioritised and assessed. Harnessing internal target gene discoveries, e-therapeutics is currently building an in-house pipeline of RNAi based medicines, using its proprietary GalNAc-siRNA technology.
e-therapeutics has deployed and validated its disease-agnostic computational drug discovery platform both in house and with partners, including Novo Nordisk, Galapagos NV and a US-based, top 5 pharmaceutical company.